Category Archives: Events

Latest From Events

The Most Linked In Man in Biotech Retires after 35 Years

Chris Y

The biotech world loses one of its preeminent titans of business development this year with the retirement of Chris Yochim. Variously dubbed “the face of AstraZeneca”, “Mr. Conference”, and other monikers as colorful as his dress shirts, Chris concludes a career spanning 35 years in the pharmaceutical industry. Trained as a pharmacologist, he contributed to the identification of several candidate compounds that are marketed drugs today, but more than anything else, Chris is known as Read More >

Events  |  1 Comment  |  Email This Post
Tags: , , , , , , , ,

#BIO2014 Blogger Roundup

Official Blogger

Want to know what’s happening at the 2014 BIO International Convention? Find out from our bloggers! #BIO2014 Opening Reception: What A Night!, San Diego Biotechnology Network BIO 2014: Training Bio-Entrepreneurs to Use Coffee, Yoga, and Data, Xconomy Liking, Sharing, and Tweeting to Better Health, The Campaign for Modern Medicines Bioethics in Compassionate Use of Drugs, Sciberomics Drug Development: An Ethical Minefield, Sciberomics National Bioscience Report Shows Industry Robust with Strong Prospects for Growth, Bravo Group Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Patent Parameters

Untitled-1

Supreme Court Finds Naturally Occurring DNA to Be Patent Ineligible Last summer, the Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., which concerned the patent eligibility of the BRCA1 and BRCA2 genes. In Myriad, a unanimous Supreme Court held that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated. The Court also determined, albeit with one caveat, that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Reimbursement Considerations for Early Stage Companies

cells115x76

Panelists at Tuesday’s breakout session – Reimbursement Considerations for Early Stage Companies – overwhelmingly agreed that emerging biotech companies must consider reimbursement at the earliest stages of development. Christopher de Wolff, MSFS, Consultant, Numerof & Associates, Inc. moderated the panel and kicked it off by pointing out that many drugs achieve regulatory approval yet fail when they reach the market because of a lack of data and evidence directed at reimbursement. He asserted that the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Turning the Tide on STEM Education

family_115x76

According to the US Department of Education, only 16 percent of American high school seniors are proficient in mathematics and interested in a career in a Science, Technology, Engineering or Math (STEM) field. Even among students who do major in a STEM field, only about half go on to work in a related career. As an industry, we have a responsibility to not only prepare today’s students for careers in STEM fields but also to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,